Table 2.

Treatment-related adverse events occurring in two or more patients (grades 1–2) or in one patient (grades 3–4)

Adverse eventaGrade 1–2Grade 3–4Total
N (%)
Hyperglycemia16 (80)3 (15)19 (95)
Thrombocytopenia12 (60)2 (10)14 (70)
Anemia13 (65)1 (5)14 (70)
Hypertriglyceridemia13 (65)1 (5)14 (70)
Cholesterol high12 (60)012 (60)
Alanine aminotransferase increased8 (40)2 (10)10 (50)
Hypoalbuminemia10 (50)010 (50)
Hyponatremia7 (35)1 (5)8 (40)
Aspartate aminotransferase increased8 (40)08 (40)
White blood cell decreased4 (20)2 (10)6 (30)
Hypocalcemia5 (25)1 (5)6 (30)
Activated partial thromboplastin time prolonged4 (20)2 (10)6 (30)
Alkaline phosphatase increased6 (30)06 (30)
Creatinine increased6 (30)06 (30)
Neutropenia2 (10)3 (15)5 (25)
Blood bilirubin increased4 (20)1 (5)5 (25)
Diarrhea5 (25)05 (25)
Lymphopenia1 (5)4 (20)5 (25)
Edema limbs4 (20)04 (20)
Mucositis4 (20)04 (20)
Cramping4 (20)04 (20)
Headache3 (15)03 (15)
Urinary tract infection2 (10)1(5)3 (15)
Anorexia2 (10)02 (10)
Epistaxis2 (10)02 (10)
Hyperkalemia2 (10)02 (10)
Hypernatremia2 (10)02 (10)
Sinusitis2 (10)02 (10)
Lung infection02 (10)2 (10)
Rash2 (10)02 (10)
Colitis01 (5)1 (5)
Encephalitis0 (0)1 (5)1 (5)
Febrile neutropenia01 (5)1 (5)
Sepsis01 (5)1 (5)
  • aNational Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0.